Integrated Filing — IndAS



General information about company

Scrip Code 517556
NSE Symbol PVP
MSEI Symbol NOTLISTED
ISIN INE362A01016
Name of company PVP VENTURES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 29-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 29-05-2026   11:00:00
End date and time of board meeting 29-05-2026   17:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 4,144.36 8,971.09
Other income 1,249.39 2,325.12
Total income 5,393.75 11,296.21
2 Expenses
(a) Cost of materials consumed 1,149.32 1,435.50
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 24.87 237.53
(d) Employee benefit expense 811.63 1,926.41
(e) Finance costs 926.88 3,350.31
(f) Depreciation, depletion and amortisation expense 987.10 1,367.05
(f) Other Expenses
1 Other Expenses 1,437.99 3,407.90
2 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 108.16
Total other expenses 1,437.99 3,516.06
Total expenses 5,337.79 11,832.86
3 Total profit before exceptional items and tax 55.96 (536.65)
4 Exceptional items (305.53) (305.53)
5 Total profit before tax (249.57) (842.18)
6 Tax expense
7 Current tax 24.86 121.16
8 Deferred tax 44.80 33.01
9 Total tax expenses 69.66 154.17
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (319.23) (996.35)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (319.23) (996.35)
17 Other comprehensive income net of taxes 276.27 303.51
18 Total Comprehensive Income for the period (42.96) (692.84)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent (36.87) (679.84)
Total profit or loss, attributable to non-controlling interests (282.36) (316.51)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 239.56 (376.17)
Total comprehensive income for the period attributable to owners of parent non-controlling interests (282.52) (316.67)
21 Details of equity share capital
Paid-up equity share capital 26,040.37 26,040.37
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 0.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0 -0.25
Diluted earnings (loss) per share from continuing operations 0 -0.25
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0 -0.25
Diluted earnings (loss) per share from continuing and discontinued operations 0 -0.25
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1 The above Consolidated Unaudited Financial Results of PVP Ventures Limited ('the Holding Company') and its subsidiaries (together referred to as the Group) for the quarter and year ended 31 March 2026 have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”) as prescribed under Section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements Regulations), 2015, as amended, (the Listing Regulations) which were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 29th May 2026. The Statutory Auditors of the Company have carried out Indepenent audit of the results for the quarter and year ended 31 March 2026. 2 The Holding Company had invested in 24,832; 22% Secured Redeemable Non-Convertible Debentures (NCDs) of Rs. 100,000 each issued by New Cyberabad City Projects Private Limited (NCCPL), erstwhile subsidiary and currently a related party of the Holding Company. Further, on 16 March 2015 the said investment of Rs. 24,832 Lakhs in debentures was converted to an Interest Free Secured loan against the security of Land owned by NCCPL and Land development rights available with NCCPL , repayable on 31 March 2017 which was further extended by 10 years to 31 March 2027. A further extension of 1 year until 31 March 2028 was granted vide supplementary agreement dated 07 February 2024. The outstanding principal loan amount as on 31 March 2026 is Rs. 21,843.49 Lakhs. Further, the status of ongoing litigation as at 31 March 2026 associated with the enforceability and market value of security is as follows: i) Attachment by Enforcement Directorate (“ED”) of the land owned by Adobe Realtors Private Limited (erstwhile stepdown subsidiary of the Company and currently related party) who have granted development rights to NCCPL Based on legal confirmation obtained by the Company from the lawyer representing the Company in the aforesaid order, the release of the said property has been ordered by the adjudicating authority vide order dated 20 December 2024. ii) Attachment by SEBI of land owned by Arete Real Estate Developers Private Limited, Expressions Real Estate Developers Private Limited (erstwhile stepdown subsidiaries of the Company and currently related parties) , who have granted development rights to NCCPL. The Honourable Supreme Court of India (“SC”) vide order dated 7 March 2025 has ordered release or attachment of the said properties in lieu of deposit of bank guarantees of amount involved in dispute and pending with the SC. The aforesaid entities and NCCPL is in the process of evaluating its options. Further, NCCPL is in the process of digitization of its land records as required in the State of Telangana. Though NCCPL is not carrying any business activity, based on the above-mentioned factors, the Company believes that while there could be a further extension of the tenor beyond the stipulated date of 31 March 2028, the amounts are fully recoverable and hence there is no necessity to create an allowance for Expected Credit Loss. i. Market value of a nearby land serving as a proxy to the land over which development rights held by NCCPL. ii. Business plans of NCCPL to monetise the land bank by developing residential and/or commercial properties. iii. Enforceable clause in the Share Purchase Agreement (SPA) which provides the first priority repayment of the loan based on the cash flows to be generated out of the project to be developed as stated in (ii) above. Additionally, the Company is guaranteed 50% payout from the revenues generated in excess of the loan outstanding, out of the sale/development of the aforesaid properties. The Holding Company believes that the provisions of Section 186(1) & 188 of the Act have been complied with to the extent applicable. Further based on internal assessment/professional opinion received in this regard, the other provisions of Section 186 of the Act in respect to loans, making investments, providing guarantees and securities are not applicable to the Company as it is involved in the business of providing infrastructural facilities. 3 During the year ended 31 March 2026, the Company has done a detailed analysis of expenditure which is incurred in the process of issuance of NCD. Transaction costs amounting to Rs. 409.19 Lakhs have been classified in accordance with Ind AS 109 and will be amortised over the tenure of the loan using the effective interest rate method, as part of borrowing costs, commencing from the quarter ended 30 June 2025. 4 The Holding Company received an email communication dated 16 July 2024 from the Corporation Finance Investigation Department of the SEBI regarding certain related party transactions undertaken in earlier financial years. The Company provided the necessary clarifications and supporting documents in response to the said communication. On 19 March 2025, 08 May 2025, 06 June 2025 and 04 September 2025 SEBI has issued summons under Section 11(2), 11C(2)/(3) of the SEBI Act, 1992 to the Company, Chief Executive Officer and the Managing Director for production of documents before the investigating authority. The summons were issued relating to loans and investments extended to the erstwhile subsidiaries—PVP Global Ventures Private Limited and PVP Media Ventures Private Limited, and Wholly owned subsidiary - Safetrunk Services Private Limited. The Holding Company has duly responded to the said summons on 01 April 2025, 16 May 2025, 23 June 2025 and 23 September 2025 providing relevant documentation and information as sought by the investigating authority. The matter continues to remain under investigation, and the outcome of the investigation is currently not ascertainable. However, the Management is confident of a favourable outcome. 5 The Holding Company has received a Show Cause Notice from the Directorate General of Goods & Services Tax Intelligence dated 22 July 2024. The notice was served on account of non-payment of GST liability by the Company, in relation to construction services provided for the North Town Project. Following this, the Company received an order dated 17 January 2025, demanding payment of Rs. 687.53 Lakhs, along with a penalty for the equivalent amount totalling to Rs. 1,375.06 Lakhs. Based on professional advice to the above notice, the Company has started availing GST Input credit on its expenses in the monthly returns being filed such that adequate credit is available to discharge the liability should the said matter be adjudicated against the Company. An amount of Rs. 75.03 lakhs has been recognized under the head “Balances with Government Authorities” grouped as part of “Other Non-Current Assets” as at 31 March 2025. Corresponding, the Management has also created a provision for contingencies amounting to Rs. 75.03 lakhs which has been presented under the head non-current provisions , to address a scenario where the said matter is decided in favour of the Company and the Company is unable to utilize the aforesaid accumulated Input tax credit. The Holding Company filed the writ petition on 15 April 2025 with the Honourable High court of Madras and by virtue of order dated 21 July 2025 - the Honourable High Court of Madras have passed the order in favour of the Company. Consequently, the accumulated input tax credit and the provision for contingency have been reversed during the year ended 31 March 2026. 6 The Holding Company is in the process of assessing its compliances under the Listing Regulations, particularly w.r.t approval of Related party transactions by the Audit committee under Regulation 23 of the Listing Regulations and the approval of material-related party transactions by the shareholders under the aforesaid Regulations. The impact of past non-compliance, if any, shall be dealt with as and when it is identified and such non-compliance if any shall not have material impact on the Financial Results for the quarter and year ended 31 March 2026. 7 The Board of Directors of the Holding Company in its Board Meeting on 12 November 2024 have provided an in-principle approval for the merger of the Company with its wholly owned subsidiary Humain Healthtech Private Limited (HHT) with an appointed date of 01 April 2024. The Company is in the process of filing the scheme of merger with the of Regional Director. 8 The Board of directors of the Holding Company in their meeting held on 28 November 2024 have approved the acquisition of 52% substantial shares of Biohygea Global Private Limited (Medilabs), while the said Share Purchase cum shareholders Agreement was finalized on the aforesaid date , and the Company had paid an advance of Rs 100 lakhs out of the total purchase consideration payable of Rs. 700 lakhs via a combination of infusion of primary growth capital into Medilabs and buying out certain portion of stake held by existing third party individual shareholders. The balance consideration of Rs. 600 lakhs was remitted during the quarter ended 30 June 2025, and accordingly, Medilabs became a subsidiary with effect from 30 April 2025. 9 The Non-Convertible Debenture Committee (“the Committee”) of the Board of Directors of the Company at its meeting held on 11 April 2025 has approved the allotment of 15,000 Secured, Rated, Listed, Non-Convertible Debentures of Face Value of Rs. 1,00,000/- each, aggregating to Rs. 15,000 lakhs on Private Placement basis in the following manner: i. 9,500 INR denominated, Listed, Rated, Senior, Secured Non-convertible Debentures (NCDs) of face value of INR 1,00,000 each aggregating up to INR 9,500 lakhs (Series A Debentures) to LICHFL Housing & Infrastructure Fund ii. 5,500 INR denominated, Listed, Rated, Senior, Secured NCDs of face value of INR 1,00,000 each aggregating up to INR 5,500 lakhs (Series B Debentures) to LICHFL Real Estate Debt Opportunities Fund –I The said NCD’s have been listed on the National Stock Exchange’s (“NSE”) debt platform. Considering that the NCDs have been issued and listed during the year ended 31 March 2026, the disclosures under Regulation 52(4) and Regulation 54(2) of the Listing Regulations have been provided in these financial results. 10 The Board of Directors of the Holding Company in their meeting held on 23 April 2025 have approved the acquisition of 56% shareholding in Optimus Oncology Private Limited (Optimus)., via a combination of infusion of primary growth capital into Optimus and buying out certain portion of the stake held by existing third party institutional and individual shareholders with the total investment being Rs. 5,473.66 lakhs with the Company holding 56.12% of the Company post-acquisition. Further, the Holding Company has also paid stamp duty amounting to Rs. 6.98 Lakhs which has been added as part of the cost of investment. Consequently, the Holding Company has entered into Shareholders’ Agreement, Share Purchase Agreement and Share subscription agreement on the aforesaid date and the acquisition was completed during the quarter ended 30 June 2025 and accordingly, Optimus became a subsidiary of the Company with effect from 30 April 2025. 11 The Board of Directors vide circular resolution dated 10 July 2024, has approved the voluntary strike off of Safetrunk Services Private Limited (SSPL) and vide order dated 8 May 2025, SSPL has been struck off from the Registrar of Companies. 12 On 04 November 2025, the Company had acquired 14,939 shares representing a stake of 33.24% of the paid up share capital of 7Med India Private Limited (7 Med) for a consideration of Rs. 6,750.19 Lakhs with the balance stake to be acquired in subsequent tranches. During the current quarter, the Nominee Directors on behalf of Parent Company have been appointed on the Board of 7 Med and hence, the balances of 7 Med have been consolidated from 1st January, 2026. 13 The Holding Company has accounted for the aforesaid business combinations in accordance with the requirements of Ind AS 103 – Business Combinations, which lays down the principles for accounting for business combinations of entities. Accordingly, the assets and liabilities have been recorded in the books of the Company at their fair value and adjustments have been made accordingly. 14 The Group has identified reportable segments in accordance with Ind AS 108-Operating Segments. Accordingly, three reportable segments, i.e. Real Estate, Health Care Services and Others have been identified the details of which are given in Segment Results - Annexure -3. 15 Previous period figures have been reclassified to conform to the current period classification/presentation. For PVP Ventures Limited Prasad V. Potluri Place : Hyderabad Chairman and Managing Director Date : Friday, May 29, 2026 DIN: 00179175



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 10,170.51
Capital work-in-progress 32.15
Investment property
Goodwill 14,679.36
Other intangible assets 7,448.42
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 594.93
Trade receivables, non-current
Loans, non-current 13,537.93
Other non-current financial assets
1 Other Financial Assets 3,693.14
Total of other non-current financial assets 3,693.14
Total non-current financial assets 17,826.00
Deferred tax assets (net) 1,154.65
Other non-current assets
1 Income Tax Assets 1,136.51
2 Other non-current assets 12,395.22
Total of other non-current assets 13,531.73
Total non-current assets 64,842.82
2 Current assets
Inventories 5,420.80
Current financial asset
Current investments 10.17
Trade receivables, current 2,614.54
Cash and cash equivalents 5,096.90
Bank balance other than cash and cash equivalents 26.60
Loans, current 435.54
Other current financial assets
Total of other current financial assets 3.42
Total current financial assets 8,187.17
Current tax assets (net) 0.00
Other current assets
1 Other current assets 944.47
Total of other current assets 944.47
Total current assets 14,552.44
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 79,395.26
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 26,040.37
Other equity (4,216.80)
Total equity attributable to owners of parent 21,823.57
Non controlling interest 18,731.20
Total equity 40,554.77
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 14,226.88
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 1,965.45
Total of other non-current financial liabilities 1,965.45
Total non-current financial liabilities 16,192.33
Provisions, non-current 140.21
Deferred tax liabilities (net) 269.67
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 9,468.81
Total of other non-current liabilities 9,468.81
Total non-current liabilities 26,071.02
Current liabilities
Current financial liabilities
Borrowings, current 9,423.53
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 6.42
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,302.16
Total Trade payable 2,308.58
Other current financial liabilities
1 Other financial liabilities 417.07
2 Lease Liabilities 27.12
Total of other current financial liabilities 444.19
Total current financial liabilities 12,176.30
Other current liabilities 207.35
1 Other current liabilities 207.35
Total of other current liabilities 207.35
Provisions, current 52.33
Current tax liabilities (Net) 333.49
Deferred government grants, Current
Total current liabilities 12,769.47
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 38,840.49
Total equity and liabilites 79,395.26
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Real Estate 1,062.33 3,292.29
2 Health Care Services 3,082.03 5,678.80
Total Segment Revenue 4,144.36 8,971.09
Less: Inter segment revenue 0.00 0.00
Revenue from operations 4,144.36 8,971.09
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Real Estate 1,756.35 3,564.08
2 Health Care Services (773.51) (642.26)
Total Profit before tax 982.84 2,921.82
i. Finance cost 926.88 3,350.31
ii. Other Unallocable Expenditure net off Unallocable income 305.53 413.69
Profit before tax (249.57) (842.18)
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Real Estate 34,224.49 34,224.49
2 Health Care Services 45,170.78 45,170.78
Total Segment Asset 79,395.27 79,395.27
Un-allocable Assets 0.00 0.00
Net Segment Asset 79,395.27 79,395.27
4 Segment Liabilities
Segment Liabilities
1 Real Estate 26,205.34 26,205.34
2 Health Care Services 12,635.15 12,635.15
Total Segment Liabilities 38,840.49 38,840.49
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 38,840.49 38,840.49
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of the defined benefit liability (5.82) (5.82)
Total Amount of items that will not be reclassified to profit and loss (5.82) (5.82)
2 Income tax relating to items that will not be reclassified to profit or loss 0.16 0.16
3 Amount of items that will be reclassified to profit and loss
1 Fair value gain/(loss) on equity investments classified as FVTOCI 282.25 309.49
Total Amount of items that will be reclassified to profit and loss 282.25 309.49
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 276.27 303.51



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (842.18)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 3,350.31
Adjustments for decrease (increase) in inventories 41.79
Adjustments for decrease (increase) in trade receivables, current (801.11)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 775.96
Adjustments for decrease (increase) in other non-current assets 3,399.04
Adjustments for other financial assets, non-current (1,723.62)
Adjustments for other financial assets, current 32.63
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (1,739.64)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (169.38)
Adjustments for increase (decrease) in other non-current liabilities (1,655.63)
Adjustments for depreciation and amortisation expense 1,367.05
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 48.92
Adjustments for provisions, non-current (41.64)
Adjustments for other financial liabilities, current (259.18)
Adjustments for other financial liabilities, non-current (568.65)
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 297.46
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 1,759.39
Net cash flows from (used in) operations 917.21
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 314.29
Other inflows (outflows) of cash (3,023.63)
Net cash flows from (used in) operating activities (2,420.71)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 3,796.09
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 0.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 6,294.78
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 281.46
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (5,456.74)
Net cash flows from (used in) investing activities (15,266.15)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 15,000.00
Proceeds from borrowings 5,258.56
Repayments of borrowings 0.00
Payments of lease liabilities 592.86
Dividends paid 0.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (650.19)
Net cash flows from (used in) financing activities 19,015.51
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1,328.65
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 1,328.65
Cash and cash equivalents cash flow statement at beginning of period 3,768.25
Cash and cash equivalents cash flow statement at end of period 5,096.90





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 PSDY & Associates, Chartered Accountants Yes 31-03-2027